The pathogenesis of acute graft-versus-host disease (aGVHD) includes tumor necrosis factor-alpha (TNFa) expression by macrophages and T cells. However, the temporal comparison of donor vs host cells to TNFa expression in response to irradiation conditioning and alloreactivity has not been reported. This study compared intracellular TNFa expression in donor vs host spleen T cells and macrophages using a murine model of aGVHD. Total body irradiation conditioning alone resulted in increased frequency of F4/80 þ /TNFa þ cells, but no increase in CD3 þ /TNFa þ cells. Syngeneic transplantation resulted in an increased frequency of F4/80 þ / TNFa þ cells, while CD3 þ /TNFa þ cells increased on days 1 and 3 but declined on day 5. Allogeneic transplantation resulted in an increased frequency of donor CD3 þ /TNFa þ cells, while the frequency of host CD3 þ /TNFa þ cells declined. Similarly, donor F4/ 80 þ /TNFa þ cells also increased in frequency after allotransplantation, while the frequency of host F4/80 þ / TNFa þ cells was increased on day 1 and declined through days 3 and 5. In absolute cell numbers, CD3 þ / TNFa þ cells were greater than F4/80 þ /TNFa þ cells post allotransplantation. We conclude that (1) both donor and host CD3 þ and F4/80 þ cells are present in the post transplant period and contribute to TNFa production and (2) in terms of frequency, the majority of TNFa producing cells in the spleen after allogeneic BMT are CD3 þ .
It is well recognized that acute graft-versus-host disease (aGVHD) is a major barrier to successful allogeneic bone marrow transplantation (BMT). The pathogenesis of aGVHD is a complex process involving multiple stimuli that include irradiation or chemotherapy conditioning, alloreactivity and gut-derived endotoxin that act to produce cell damage and a variety of intercellular mediators. Tumor necrosis factor-alpha (TNFa) is a major component of aGVHD pathogenesis and participates in the development of an inflammatory cytokine storm or cytokine dysregulation following both conditioning and alloreactivity. [1] [2] [3] Evidence for a significant role of TNFa in aGVHD includes human clinical studies demonstrating improved resolution of GVHD following treatment with anti-TNF antibodies. 4, 5 In murine studies, reduced aGVHD is also observed following the administration of anti-TNF antibodies [6] [7] [8] or the use of TNF receptordeficient BMT recipients. 9, 10 It is generally accepted that a major source of TNFa is activated monocytes/macrophages without knowing whether they are of host and/or donor origin. In the context of GVHD, major stimuli of TNFa in macrophages include irradiation conditioning and gut-derived endotoxin acting on IFNg primed macrophages. 11, 12 However, other cell types including T cells, NK cells, and endothelial cells are capable of producing TNFa. In particular, T lymphocytes are the primary site of allorecognition. Recently, it has been shown that TNF produced by murine donor T cells is involved in both GVHD and the graft-versusleukemia (GVL) effect. 13 This finding suggests that donor T lymphocytes also contribute to TNFa production. Our previous studies have demonstrated that irradiation conditioning activates the transcription factor NF-kB primarily in various lymphoid and hematopoietic tissues, including the spleen which is rich in both T cells and macrophages. 14, 15 Since TNFa transcription is NF-kB dependent, 16 this suggests that host lymphocytes (T cells) and macrophages may also contribute to TNFa release following pretransplant irradiation conditioning and allotransplantation. Thus, the present study is designed to test the hypothesis that TNFa is produced by both donor and host cells post irradiation conditioning and allotransplantation, probably in a temporal manner. Accordingly, we determined the relative frequency of TNFa production in donor vs host CD3 þ T cells and F4/80 þ macrophages in the spleen following irradiation conditioning, syngeneic, and allogeneic spleen cell transplantation. The results demonstrate (1) the transition of TNFa production from donor host to cells in the spleen and (2) that in terms of frequency, CD3 þ /TNFa þ cells are greater than F4/80 þ / TNFa þ cells.
Methods

Mice
Male BALB/c and C57BL/6 mice were obtained through the National Cancer Institute and used at 8-12 weeks of age. They were housed in microisolators at the AAALAC approved facilities at the Veterans Affairs Medical Center, Lexington, KY and received food and water ad libitum. The Institutional Animal Studies Committee approved all procedures.
Spleen cell transplantation
Recipient BALB/c mice (H-2 d ) were conditioned with 8.5 Gy of total body irradiation (TBI) at a dose rate of 2.0 Gy/min using a Shepard Model Mark I-68 137 Cs irradiator. Donor C57BL/6 mice (H-2 b ) were euthanized with CO 2 and a whole spleen cell suspension was prepared in USP normal saline. Transplantation was performed 1-2 h post irradiation by injecting 50 Â 10 6 spleen mononuclear cells (MNC) i.v. through a tail vein. At the indicated times post transplantation, the mice were euthanized using CO 2 and a whole spleen cell suspension was prepared by mincing and passage through a wire mesh. The spleen cells were then washed, counted, and stained for flow cytometry analysis.
Monoclonal antibodies
The following monoclonal antibodies and their isotype controls were used for three-color flow cytometry analysis: Biotinylated anti-mouse H-2D d (clone 34-2-12), biotinylated anti-mouse H-2K b (clone KH95), FITC anti-mouse CD3-e (clone 145-2C11), and FITC anti-mouse macrophage (clone F4/80). Intracellular TNFa was detected by PE anti-mouse TNFa (clone MP6-XT22). MP6-XT22 is a standard antibody used for intracellular TNFa detection. However, its crossreactivity with TNFb has not been determined. All antibodies were obtained from BDBiosciences, San Diego, CA, USA or CalTag Laboratories, Burlingame, CA, USA.
Intracellular TNFa staining
Staining for intracellular TNFa was performed using the CytoStain assay system from BD Biosciences, Inc. (San Diego, CA, USA). Briefly, a single-cell suspension of spleen cells was prepared and incubated for 2 h with 500 ng/ml ionomycin and 10 ng/ml PDBU. Monensin (GolgiStop) was then added for an additional 2 h of incubation, according to the CytoStain protocol. FcgII/III receptors were blocked by incubation with 1 mg of anti-mouse CD16/ CD32 monoclonal antibody (clone 2.4G2) per 10 6 cells for 20 min. Cell surface antigen staining was carried out with the appropriate antibodies followed by fixation and permeabilization of the cell membrane using the supplied cytofix/cytoperm reagent. Intracellular TNFa was stained using PE-conjugated anti-TNFa. Three-color flow cytometry analysis was then performed with initial gating on the H-2 phenotype to distinguish donor vs host cells. The isotype control value was subtracted and the results were calculated as the total number of positive spleen cells.
Endotoxin determination
Endotoxin levels were determined in the spleen, liver, and serum of recipient mice, using the Pyrotel LAL Gel Clot Assay (Associates of Cape Cod, Inc., Woods Hole, MA, USA). Sterile spleen and liver homogenates were prepared in pyrogen-free saline and serial 10-fold dilutions analyzed. The starting dilutions were 1:10 for liver and spleen, 1:50 for serum and were based on the background level in normal control mice. Endotoxin standards (E. coli 0113) were diluted in LAL Reagent Water and served as controls for the samples. The total endotoxin units (EU) were calculated for each experimental sample using the highest dilution at which gel clot formation occurred.
Results
Repopulation of the spleen by donor cells
To determine the kinetics of spleen cell depletion and repopulation in this model of aGVHD, the numbers of donor and host MNC, CD3 þ , and F4/80 þ cells were determined. In the absence of transplantation, 8.5 Gy TBI resulted in a rapid decrease in the number of spleen cells. The MNC levels decreased from an average of 109 Â 10 6 in normal nonirradiated control mice to 24 Â 10 6 on day þ 1 post irradiation ( Figure 1a ). On days 3 and 5 post TBI, spleen MNC continued to decrease to 6% of normal values. In contrast, TBI followed by syngeneic transplantation with 50 Â 10 6 spleen cells resulted in decreased but stable levels of spleen cells with an average of 28.8, 25.0, and 24.6 Â 10 6 spleen MNC on days 1, 3, and 5 post transplantation, respectively. Compared to syngeneic transplantation, TBI followed by allogeneic transplantation resulted in an initial decrease followed by increasing numbers of spleen MNC on days 1, 3, and 5 with an average total MNC of 36.7, 30.3, and 59.7 Â 10 6 , respectively. Thus, by day 5 post allotransplant, MNC levels had returned to 55% of control mice.
Analysis of the number of donor vs host cells in the spleen was performed after allogeneic transplantation ( Figure 1b ). An increasing shift from recipient phenotype (H-2D 
Intracellular TNFa expression
In order to determine the contribution of donor and host cells to TNFa production, intracellular (cytoplasmic) TNFa expression in CD3 þ T cells and F4/80 þ macrophages was determined in normal BALB/c mice, and on days 1, 3, and 5 following TBI, TBI þ syngeneic transplantation, and TBI þ allogeneic transplantation (Figures 3 and 4) .
Following allogeneic transplantation, the number of host CD3 þ /TNFa þ cells remained constant on day 1 but declined on day 3 and continued declining to 8% of day 0 levels by day 5. In contrast, donor CD3 þ /TNFa þ cells increased on days 1, 3, and 5 such that by day 5, donor CD3 þ /TNFa þ cells were 500% of day 0 host values and represented 98% of total spleen CD3 þ cells. Analysis of host F4/80 þ /TNFa þ cells demonstrated a 21-fold increase on day 1 followed by a decline through day 5. In contrast, donor F4/80 þ /TNFa þ cells increased through days 1, 3, and 5 post transplantation. Significantly, on day 1, the total number of host and donor F4/80 þ /TNFa þ cells was higher than that found in day 0 normal control mice. On day 5, when donor cells were predominant, CD3 þ /TNFa þ cells outnumbered F4/80 þ /TNFa þ cells by a ratio of almost 5:1.
Syngeneic transplantation after irradiation resulted in an initial increase in CD3 þ /TNFa þ on days 1 and 3. Unlike allotransplantation, this was followed by a rapid decline on day 5. Compared to untreated day 0 control values, F4/ 80 þ /TNFa þ cells significantly increased on day 1 and then declined on days 3 and 5. TBI conditioning alone resulted in similar levels of CD3 þ /TNFa þ cells on days 0, 1, and 5. F4/80 þ / TNFa þ cells were increased compared to untreated controls on all 3 days post TBI. They peaked on day 3 and were higher than control levels on days 1 and 5.
Endotoxin levels
In order to determine if elevated endotoxin was contributing to the induction of TNFa production, endotoxin levels in the liver, spleen, and serum samples following TBI alone, syngeneic or allogeneic transplantation ( Figure 5 ) were compared. In allotransplantation, endotoxin was detected only on day 5 in 64% of serum samples and 72% of spleen samples. In this transplant model, severe aGVHD is present on day 5. No endotoxin was detected in the liver (days 1, 3, or 5) or on days 1 and 3 in serum or spleen samples after allotransplantation. Irradiation followed by syngeneic transplantation did not result in detectable endotoxin in any tissue tested. Following 8.5 Gy TBI of normal host (BALB/c) mice, 25% of spleen and 13% of the serum samples were positive for endotoxin on day 3.
Discussion
The development of aGVHD is primarily dependent upon two types of immune cells: T cells and antigen-presenting cells. It is initiated by donor T-cell recognition of host alloantigens present in a variety of target tissues. 17, 18 This recognition is dependent upon host antigen-presenting cells presenting host antigens to donor T cells. 19 The removal or inactivation of either of these cells will reduce aGVHD in mismatched BMT. Additionally, the importance of pretransplant conditioning in the development of GVHD in conjunction with alloreactivity has been demonstrated in numerous studies. [20] [21] [22] [23] The conditioning initiates an inflammatory 'cytokine storm' in the recipient that includes TNFa expression and plays a significant role in aGVHD pathogenesis. Thus, this study was designed to test the hypothesis that TNFa is produced by both donor and host cells after irradiation conditioning and allotransplantation. An in vivo murine model was used to compare the frequency of CD3 þ vs F4/80 þ cells expressing TNFa after TBI conditioning and TBI followed by syngeneic or allogeneic spleen cell transplantation. The spleen was selected for analysis because it is a major immune organ that contains abundant CD3 þ and F4/80 þ cells. The results demonstrate that both donor and host CD3 þ T cells and F4/80 þ macrophages produce TNFa in the recipient spleen. In terms of frequency, the number of CD3 þ spleen cells producing TNFa is greater than the number of F4/80 þ cells.
The comparison of TBI conditioned mice to normal spleen cells demonstrated that increased TNFa expression occurs in F4/80 þ cells. TBI-induced TNFa expression in host F4/80 þ cells is transient, peaks on day 3 post TBI, and resolves in the absence of alloreactivity. Studies by others have shown that irradiation primes macrophages to secrete TNFa in response to LPS. 20, 24 This priming is rapid and occurs by 4 h after irradiation. Thus, the appearance of increased host F4/80 þ /TNFa þ cells on day 1 suggests that their increased production of TNFa may be the result of direct activation of macrophages by preconditioning irradiation and/or stimulation by endotoxin from the irradiation damaged gut. In a recent study, early TNFa production by murine bone marrow macrophages was enhanced by a combination of LPS and apoptotic cells. 25 Thus, the phagocytosis of irradiation-induced apoptotic cells by F4/80 þ macrophages may also contribute to TNFa production. Although the presence of endotoxin is below the detectable level on day 1 after TBI, the day 3 peak in F4/80 þ /TNFa þ cells after TBI conditioning correlates with the detection of endotoxin in 25% of the spleen samples. The major contribution of host macrophages to TNFa production may therefore occur only after subsequent stimulation by endotoxin entering the circulation due to irradiation damage to the gut.
In contrast to the increased number of F4/80 þ cells following TBI only, the number of host CD3 þ / TNFa þ spleen cells remained essentially unchanged on days 0, 1, and 5. This maintenance of CD3 þ /TNFa þ cell numbers occurred during a large decline in the overall number of host CD3 þ cells. In support of this, irradiation has been shown to induce the production of TNFa in human T cells and induce the accumulation of TNFa mRNA in human T lymphocytes depleted of contaminating macrophages. 26 In addition, a number of human recipient T cells have been shown to survive chemotherapy and irradiation conditioning, proliferate in response to PHA, IL-2, and alloantigens in the mixed lymphocyte reaction, and exhibit cell-mediated cytotoxicity. 27 Since TNFg has been shown to act as a radio-protecting agent, 28, 29 this suggests a mechanism for host T cell persistence in the initial post irradiation period. Specifically, those host T cells producing TNFa in response to irradiation may have a survival advantage in the days immediately following TBI and transplantation.
TBI followed by syngeneic transplantation resulted in an increased number of CD3 þ /TNFa þ cells on days 1 and 3 that declined on day 5 to levels significantly less than the nonirradiated controls. Compared to TBI alone, TBI þ syngeneic transplantation resulted in a greater number of CD3 þ /TNFa þ cells. This suggests that donor CD3 þ cells were induced to produce TNFa on days 1 and 3 by the TBI-induced inflammatory environment in the syngeneic host. As with TBI alone, TBI þ syngeneic transplantation resulted in a significant increase in F4/ 80 þ cells producing TNFa. This was maximal on day 1 post transplant and declined through day 5. This response occurred in the absence of detectable endotoxin, suggesting that TBI may have primed the F4/80 þ cells (by inducing IFNg) to produce TNFa in response to low-level endotoxin.
The largest increase in TNFa producing cells occurred after TBI þ allotransplantation. While the number of host CD3 þ /TNFa þ cells in the spleen declined, donor CD3 þ /TNFa þ cells increased. A similar pattern was observed in donor F4/80 þ cells. In support of this, vigorous proliferation of donor cells in response to both major and minor histocompatibility antigens has been reported on day 3 post transplantation in cell-tracking studies. 30 In terms of absolute numbers, CD3 þ /TNFa þ out number F4/80 þ /TNFa þ cells in the spleen by a 5:1 ratio on day 5 post allotransplantation.
The endotoxin levels observed in these studies are similar to studies reported by others. 12, 31 Specifically, maximal endotoxin levels and the appearance of endotoxin in the serum have been observed immediately prior to death from aGVHD. In the model used here, 8.5 Gy followed by transplantation with 50 Â 10 6 donor spleen cells produces an accelerated aGVHD typically resulting in death on day 6-7. Thus, by day 5 post transplant, gut damage from the combination of irradiation and aGVHD is severe and leads to the massive influx of endotoxin into the circulation (serum) and uptake by endotoxin receptors in the spleen and liver. However, this present study did not demonstrate the early (days 1-2) appearance of endotoxin and did not find endotoxin in the liver as reported in studies using nonirradiated F1 recipients and parental donors. 31 Significant differences between these two models exist. First, the appearance of early endotoxin in nonirradiated F1 recipients indicates more rapid damage to the gut. This suggests that the presence of undamaged, intact host immune cells in nonirradiated F1 recipients generates more severe GVHD in the gut with the resulting earlier appearance of endotoxin. Second, the lack of liver endotoxin in our study suggests that this accelerated GVHD model induces death before endotoxin bound to receptors in the liver reaches detectable levels.
These results lead to several conclusions. First, a population of host T cells and macrophages initially survive conditioning and generate a TNFa response in the spleen. Thus, TNFa expression is initiated in host cells by pretransplant irradiation conditioning and is continued by donor cells recognizing alloantigens. The transition of TNFa expression from host to donor cells includes an immediate post transplant period in which both types of cells are coexpressing TNFa. Alterations in transplantation technique such as T-cell depletion would be expected to modify (decrease) initial donor T-cell-derived TNFa levels. Therefore, the kinetics of TNFa production by T cells is probably dependent upon the transplantation protocol. The second conclusion is that in this aGVHD model, the frequency of CD3 þ /TNFa þ spleen cells is greater than F4/80 þ / TNFa þ cells, suggesting that CD3 þ cells may be an important producer of TNFa in BMT. This study did not determine the relative amounts of TNFa produced by each cell type or the total contribution of each cell type to overall TNFa production. Indeed, in target tissues rich in macrophages, such as the liver, CD3 þ cells may not be a significant source of TNFa. Likewise, in the hematopoietic system, the primary target of conditioning and alloreactivity, TNFa production may predominate in T cells. Overall, TNFa-producing cells in the spleen include both donor and host CD3 þ and F4/80 þ cell populations.
